Scholarlink

<p>The rise of ESBL-producing Enterobacteriaceae and vancomycin-resistant enterococci (VRE) has limited treatment choices, underscoring the need for new antimicrobials. <i>Pleurotus</i> species have bioactive compounds with medicinal potential. This study examined the antibacterial, antioxidant, cytotoxic, and molecular interaction activities of <i>Pleurotus ostreatus</i> and <i>pulmonarius</i> extracts against multidrug-resistant bacteria. Authenticated mushroom samples were extracted. Agar well diffusion and broth microdilution were used to test antibacterial efficacy against clinical ESBL-producing <i>Escherichia coli</i>, <i>Klebsiella pneumoniae</i>, vancomycin-resistant <i>Enterococcus faecalis</i>, and <i>E. faecium</i>. The DPPH and FRAP assays measured antioxidant activity, while the MTT assay measured cytotoxicity on Vero cell lines. GC–MS profiling tentatively identified major volatile and semi-volatile phytochemicals based on library matching, followed by ProTox-3 in silico toxicity prediction and molecular docking against essential bacterial targets. Ethanolic extracts outperformed aqueous extracts in antibacterial activity, with 21.5 ± 0.8&#xa0;mm inhibition zones against ESBL-producing <i>E. coli</i> and minimum inhibitory concentrations of 6.25&#xa0;mg/mL. Antioxidant analysis showed moderate radical-scavenging and reducing activity, with IC50 values of 48.6 ± 1.2&#xa0;µg/mL (<i>P. ostreatus</i>) and 52.3 ± 1.5&#xa0;µg/mL (<i>P. pulmonarius</i>) in the DPPH assay and supportive FRAP responses. Cytotoxicity examination revealed relatively high CC<sub>50</sub> values (182.4 ± 4.6&#xa0;µg/mL and 195.1 ± 5.2&#xa0;µg/mL); however, after correcting for unit consistency between CC<sub>50</sub> and MIC, the selectivity indices were &lt; 1, indicating limited selectivity at the tested concentrations. Major volatile constituents tentatively identified by GC–MS included hexadecanoic acid (23.4%), linoleic acid (18.7%), and ergosterol (11.2%), although these peak-area percentages represent relative signal abundance rather than absolute quantification. Docking studies indicate possible binding interactions of identified metabolites with selected bacterial targets, while predicted toxicity suggested low predicted hazard only and does not establish safety. <i>Pleurotus</i> extracts showed moderate antibacterial and antioxidant activity with minimal in vitro cytotoxicity in Vero cells, but the SI values indicate limited antibacterial selectivity at the tested concentrations. These findings should therefore be regarded as preliminary and not as evidence of clinical or therapeutic applicability.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Evaluation of Antibacterial, Antioxidant, and Cytotoxic Properties of Pleurotus Mushroom Extracts Against ESBL-Producing and Vancomycin-Resistant Bacteria

  • 期刊论文

  • 发表日期：

    2026年6月26日

查看全文
  • Ghadah S. Abusalim,
  • Mohammed Alissa

摘要

The rise of ESBL-producing Enterobacteriaceae and vancomycin-resistant enterococci (VRE) has limited treatment choices, underscoring the need for new antimicrobials. Pleurotus species have bioactive compounds with medicinal potential. This study examined the antibacterial, antioxidant, cytotoxic, and molecular interaction activities of Pleurotus ostreatus and pulmonarius extracts against multidrug-resistant bacteria. Authenticated mushroom samples were extracted. Agar well diffusion and broth microdilution were used to test antibacterial efficacy against clinical ESBL-producing Escherichia coli, Klebsiella pneumoniae, vancomycin-resistant Enterococcus faecalis, and E. faecium. The DPPH and FRAP assays measured antioxidant activity, while the MTT assay measured cytotoxicity on Vero cell lines. GC–MS profiling tentatively identified major volatile and semi-volatile phytochemicals based on library matching, followed by ProTox-3 in silico toxicity prediction and molecular docking against essential bacterial targets. Ethanolic extracts outperformed aqueous extracts in antibacterial activity, with 21.5 ± 0.8 mm inhibition zones against ESBL-producing E. coli and minimum inhibitory concentrations of 6.25 mg/mL. Antioxidant analysis showed moderate radical-scavenging and reducing activity, with IC50 values of 48.6 ± 1.2 µg/mL (P. ostreatus) and 52.3 ± 1.5 µg/mL (P. pulmonarius) in the DPPH assay and supportive FRAP responses. Cytotoxicity examination revealed relatively high CC50 values (182.4 ± 4.6 µg/mL and 195.1 ± 5.2 µg/mL); however, after correcting for unit consistency between CC50 and MIC, the selectivity indices were < 1, indicating limited selectivity at the tested concentrations. Major volatile constituents tentatively identified by GC–MS included hexadecanoic acid (23.4%), linoleic acid (18.7%), and ergosterol (11.2%), although these peak-area percentages represent relative signal abundance rather than absolute quantification. Docking studies indicate possible binding interactions of identified metabolites with selected bacterial targets, while predicted toxicity suggested low predicted hazard only and does not establish safety. Pleurotus extracts showed moderate antibacterial and antioxidant activity with minimal in vitro cytotoxicity in Vero cells, but the SI values indicate limited antibacterial selectivity at the tested concentrations. These findings should therefore be regarded as preliminary and not as evidence of clinical or therapeutic applicability.